{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:02:55Z","timestamp":1790614975373,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T00:00:00Z","timestamp":1255996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p>\n                    <jats:bold>Background and purpose:\u2002<\/jats:bold>\n                    Hyperlipidaemia interferes with cardioprotective mechanisms, but the cause of this phenomenon is largely unknown, although hyperlipidaemia impairs the cardioprotective NO\u2013cGMP system. However, it is not known if natriuretic peptide\u2013cGMP\u2013protein kinase G (PKG) signalling is affected by hyperlipidaemia. Therefore, we investigated the cardioprotective efficacy of cGMP\u2010elevating agents in hearts from normal and hyperlipidaemic rats.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Experimental approach:\u2002<\/jats:bold>\n                    Male Wistar rats were rendered hyperlipidaemic by feeding with 2% cholesterol\u2010enriched chow for 12 weeks. Hearts isolated from normal and hyperlipidaemic rats were perfused (Langendorff mode) and subjected to 30\u2003min occlusion of the left main coronary artery, followed by 120\u2003min reperfusion. 8\u2010Br\u2010cGMP (CG, 10\u2003nM), B\u2010type natriuretic peptide\u201032 (BNP, 10\u2003nM),\n                    <jats:italic>S<\/jats:italic>\n                    \u2010nitroso\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010acetyl\u2010penicillamine (SNAP, 1\u2003\u00b5M) were perfused from 10\u2003min prior to coronary occlusion until the 15th min of reperfusion. Infarct size (% of ischaemic risk zone) was determined by triphenyltetrazolium staining.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key results:\u2002<\/jats:bold>\n                    Treatment with CG, SNAP or BNP decreased infarct size significantly in normal hearts from its control value of 41.6 \u00b1 2.9% to 15.5 \u00b1 2.4%, 23.3 \u00b1 3.0% and 25.3 \u00b1 4.6%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). Protection by BNP was abolished by co\u2010perfusion of PKG inhibitors KT5823 (600\u2003nM) or Rp\u20108pCPT\u2010PET\u2010cGMPs (1\u2003\u00b5M), confirming its PKG dependence. In hearts from hyperlipidaemic rats, CG, SNAP or BNP failed to decrease infarct size. Hyperlipidaemia did not alter basal myocardial PKG content, but decreased its activity as assessed by phosphorylation of cardiac troponin I.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions and implications:\u2002<\/jats:bold>\n                    This is the first demonstration that defects in the cardioprotective cGMP\u2013PKG system could be a critical biochemical anomaly in hyperlipidaemia.\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2009.00424.x","type":"journal-article","created":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T15:55:35Z","timestamp":1256054135000},"page":"1495-1502","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hyperlipidaemia induced by a high\u2010cholesterol diet leads to the deterioration of guanosine\u20103\u2032,5\u2032\u2010cyclic monophosphate\/protein kinase G\u2010dependent cardioprotection in rats"],"prefix":"10.1111","volume":"158","author":[{"given":"Z","family":"Giricz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"G\u00f6rbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Pipis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DS","family":"Burley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GF","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707746"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144318"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-007-0672-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707409"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.10.021"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00772.2005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M801547200"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00902.2002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.88.2.e12"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705080"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.107.06002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-003-0412-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.091140"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.11.023"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/152308604322899396"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1514-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2001.014126"},{"issue":"35","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"26286","DOI":"10.1016\/S0021-9258(19)74313-0","article-title":"Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP\u2010inhibited and cGMP\u2010stimulated phosphodiesterases through guanylyl cyclase activation","volume":"268","author":"Mery PF","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000094403.78467.C3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.87.11.999"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(03)00330-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2006.10.018"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(04)00189-9"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00954.2003"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2520269"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007828804553"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/107424840000500108"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-817978"},{"issue":"5","key":"e_1_2_8_30_1","first-page":"H2033","article-title":"Ventricular overdrive pacing\u2010induced anti\u2010ischemic effect: a conscious rabbit model of preconditioning","volume":"266","author":"Szilvassy Z","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200007000-00003"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.566190"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00440-4"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02133-2"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00882.2003"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-006-0587-2"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.52.37429"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2009.00424.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2009.00424.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:19:08Z","timestamp":1697415548000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2009.00424.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,28]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1476-5381.2009.00424.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00424.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,28]]},"assertion":[{"value":"2009-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}